Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Leo Pharma Acquires Global Rights to Atopic Dermatitis Treatment in $580 Million Deal

publication date: Apr 15, 2020

Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma in an agreement worth up to $570 million. FB825 is a first-in-class candidate that targets the CεmX domain of membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells and slowing the immune response, the company said. Leo acquired FB825 from Oneness Biotech of Taiwan and Microbio Shanghai. It made a $40 million upfront payment and will pay up to $530 million of milestones, plus royalties. More details....

Stock Symbol: (TPEx: 4743)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.